Sunday, September 14, 2014

2014 Fantasy NRL season is over (sportsbet.com.au)

Congrats to Shevket's Shevs Boys team which is this season's winner. This prize is a stressful $5,000 free bet.

Shevket is a very deserving winner he build a very balanced and strong town from the beginning of the season. He then managed his trades well enough to dominate the Leaderboard all season long while thousands of us tried to chase him down. Well done Shevket and good luck with that prize!

I finished ranked 19th overall so no major prizes for me but I won four of my League finals and had fun playing. I may play again next season if I have time.

Thursday, September 4, 2014

ASX Sharemarket Game 2 2014 - update

After a month in this competition Becky from NSW is our clear leader with a huge portfolio return of 65.4%. Second is Jakem from Victoria with am impressive return of 41.4%. The All Ord Index has returned 5.6% over this same time-period.

I am ranked 28th with a return of 18.4%. I am pleased to have climbed onto the Leaderboard but am still a long way from the summit so I will be sticking with a most aggressive strategy to try and get to the summit. This competition has only 1 prize for the winner so finishing second or last all pay the same. Check my performance summary below:



I am currently fully invested in my favorite biotechnology sector. My two largest holdings are MSB.AX (Mesoblast) and SRX.AX (Sirtex).

Mesoblast is my best performer, since August this stock is up over 36%. The catalyst for their sharp price movement was their company announcement that they had entered into an agreement with The US National Institute of Health to run a 120-patient trial in end-stage heart failure using their adult stem cell therapy.
Not sure how much higher this stock will run in the short term, I will continue to hold it until it shows weakness. From a longer-term investment perspective I think this stock has tremendous potential. Below is their 12 month chart:
















Sirtex has been trending strongly also, its August return was over 24%.
Sirtex's price has benefited from strong sales growth of their liver cancer treatments. They also have more liver cancer treatments being trialed in their pipeline. I like this company's short and long term prospects.














I wont disclose any more of my holdings for now, I am chasing the main prize!


Note - The mentioned stocks are traded in a stock market game simulator. Real money is not used.